# EDGAR Filing Document

**Accession Number:** 0001637715
**File Stem:** 0001193125-26-146025
**Filing Date:** 2026-4
**Character Count:** 22401
**Document Hash:** 8d0dda4da780b5fbcbf1a3f77c260163
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-146025.hdr.sgml**: 20260407

**ACCESSION NUMBER**: 0001193125-26-146025

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260407

**DATE AS OF CHANGE**: 20260407

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OnKure Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001637715
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472309515
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92480
- **FILM NUMBER:** 26846276

**BUSINESS ADDRESS:**
- **STREET 1:** 6707 WINCHESTER CIRCLE, SUITE 400
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** (720) 307-2892

**MAIL ADDRESS:**
- **STREET 1:** 6707 WINCHESTER CIRCLE, SUITE 400
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Reneo Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20150325
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AI Biotechnology LLC
- **CENTRAL INDEX KEY:** 0001942670

**ORGANIZATION NAME:**
- **EIN:** 842172770
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ACCESS INDUSTRIES, INC.
- **STREET 2:** 40 WEST 57TH STREET, 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212-247-6400

**MAIL ADDRESS:**
- **STREET 1:** C/O ACCESS INDUSTRIES, INC.
- **STREET 2:** 40 WEST 57TH STREET, 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_4.pdf`

_No text found in this document._

**Attachment 2:** `ck0000000000-ex99_5.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**OnKure Therapeutics, Inc.**

*(Name of Issuer)*

**Class A Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Alejandro Moreno**<br>c/o Access Industries, Inc.<br>40 West 57th Street, 28th Floor<br>New York NY 10019<br>(212) 247-6400

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/31/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**AI Biotechnology LLC** | Name of reporting person<br>**AI Biotechnology LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9091532.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9091532.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9091532.00** | Aggregate amount beneficially owned by each reporting person<br>**9091532.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1)  The total number of shares of Class A Common Stock, par value $0.0001 per share ("Class A Common Stock") of OnKure Therapeutics, Inc. (the "Issuer") reported as beneficially owned includes (i) 3,998,332 shares of Class A Common Stock held directly by AI Biotechnology LLC ("AIB") and (ii) 5,093,200 shares of Class A Common Stock issuable upon the partial exercise of the Pre-Funded Warrants (as defined in Item 3 herein) held directly by AIB, which are exercisable at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker (as defined in Item 5 herein).

(2)  The percent of Class A Common Stock reported as beneficially owned is calculated based on the number of shares of Class A Common Stock described in footnote (1) above and, as the denominator, the sum of (i) 40,387,201 shares of Class A Common Stock outstanding, comprised of 13,673,565 shares outstanding, as set forth in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, plus 26,713,636 shares of Class A Common Stock issued in the private placement, as described in the Issuer's Current Report on Form 8-K filed with the SEC on March 30, 2026 and (ii) 5,093,200 shares of Class A Common Stock issuable upon the partial exercise of Pre-Funded Warrants held by AIB.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Access Industries Holdings LLC** | Name of reporting person<br>**Access Industries Holdings LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9091532.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9091532.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9091532.00** | Aggregate amount beneficially owned by each reporting person<br>**9091532.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1)  The total number of shares of Class A Common Stock of the Issuer reported as beneficially owned includes (i) 3,998,332 shares of Class A Common Stock held directly by AIB and (ii) 5,093,200 shares of Class A Common Stock issuable upon the partial exercise of the Pre-Funded Warrants held directly by AIB, which are exercisable at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker.

(2)  The percent of Class A Common Stock reported as beneficially owned is calculated based on the number of shares of Class A Common Stock described in footnote (1) above and, as the denominator, the sum of (i) 40,387,201 shares of Class A Common Stock outstanding, comprised of 13,673,565 shares outstanding, as set forth in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, plus 26,713,636 shares of Class A Common Stock issued in the private placement, as described in the Issuer's Current Report on Form 8-K filed with the SEC on March 30, 2026 and (ii) 5,093,200 shares of Class A Common Stock issuable upon the partial exercise of Pre-Funded Warrants held by AIB.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Access Industries Management, LLC** | Name of reporting person<br>**Access Industries Management, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9091532.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9091532.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9091532.00** | Aggregate amount beneficially owned by each reporting person<br>**9091532.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1)  The total number of shares of Class A Common Stock of the Issuer reported as beneficially owned includes (i) 3,998,332 shares of Class A Common Stock held directly by AIB and (ii) 5,093,200 shares of Class A Common Stock issuable upon the partial exercise of the Pre-Funded Warrants held directly by AIB, which are exercisable at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker.

(2)  The percent of Class A Common Stock reported as beneficially owned is calculated based on the number of shares of Class A Common Stock described in footnote (1) above and, as the denominator, the sum of (i) 40,387,201 shares of Class A Common Stock outstanding, comprised of 13,673,565 shares outstanding, as set forth in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, plus 26,713,636 shares of Class A Common Stock issued in the private placement, as described in the Issuer's Current Report on Form 8-K filed with the SEC on March 30, 2026 and (ii) 5,093,200 shares of Class A Common Stock issuable upon the partial exercise of Pre-Funded Warrants held by AIB.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Len Blavatnik** | Name of reporting person<br>**Len Blavatnik** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9091532.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9091532.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9091532.00** | Aggregate amount beneficially owned by each reporting person<br>**9091532.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1)  The total number of shares of Class A Common Stock of the Issuer reported as beneficially owned includes (i) 3,998,332 shares of Class A Common Stock held directly by AIB and (ii) 5,093,200 shares of Class A Common Stock issuable upon the partial exercise of the Pre-Funded Warrants held directly by AIB, which are exercisable at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker.

(2)  The percent of Class A Common Stock reported as beneficially owned is calculated based on the number of shares of Class A Common Stock described in footnote (1) above and, as the denominator, the sum of (i) 40,387,201 shares of Class A Common Stock outstanding, comprised of 13,673,565 shares outstanding, as set forth in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, plus 26,713,636 shares of Class A Common Stock issued in the private placement, as described in the Issuer's Current Report on Form 8-K filed with the SEC on March 30, 2026 and (ii) 5,093,200 shares of Class A Common Stock issuable upon the partial exercise of Pre-Funded Warrants held by AIB.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
OnKure Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
6707 Winchester Circle, #400, Boulder, CO, 80301

**Item 4. Purpose of Transaction**

The information set forth in Item 3 and Item 6 hereof is hereby incorporated herein by reference.

The Reporting Persons who hold securities of the Issuer directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer. Dr. Liam Ratcliffe, who is currently employed by Access Industries, Inc., an affiliate of AIB, as its Head of Biotechnology, serves on the board of directors of the Issuer (in connection with the board designation right set forth in the Securities Purchase Agreement, as described in Item 3). The Reporting Persons intend to re-examine their investment from time to time and, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem material, the Reporting Persons may from time to time acquire additional securities of the Issuer in the open market, block trades, negotiated transactions, or otherwise and may also dispose of all or a portion of the Issuer's securities, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Issuer's securities, in each case, subject to limitations under applicable law.

The Reporting Persons have not yet determined which, if any, of the above courses of action they may ultimately take. The Reporting Persons' future actions with regard to the Issuer are dependent on their evaluation of the factors listed above, circumstances affecting the Issuer in the future, including prospects of the Issuer, general market and economic conditions and other factors deemed relevant. The Reporting Persons reserve the right to determine in the future whether to change the purpose or purposes described above or whether to adopt plans or proposals of the type specified above or otherwise.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Class A Common Stock (including but not limited to footnotes to such information) are incorporated herein by reference.

The Pre-Funded Warrants may not be exercised if the aggregate number of shares of Class A Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the Class A Common Stock outstanding, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AIB may increase or decrease the foregoing beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (such limitations, the "Beneficial Ownership Blocker"). As of the date of this filing, and pursuant to the Beneficial Ownership Blocker, 40,383 shares of Class A Common Stock are issuable at any time or times upon the partial exercise of the Pre-Funded Warrants and 5,093,200 shares of Class A Common Stock are issuable upon the partial exercise of the Pre-Funded Warrants, if AIB delivered notice to the Issuer to increase the beneficial ownership limitation to 19.99% (such notice not to be effective until the sixty-first day after the date such notice is delivered to the Issuer).

**(b)**
The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of shares of Class A Common Stock as to which each of the Reporting Persons has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

3,998,332 shares of Class A Common Stock and Pre-Funded Warrants exercisable into 5,640,222 shares of Class A Common Stock, of which 5,093,200 may be deemed to be beneficially owned as of the date of this filing pursuant to the Beneficial Ownership Blocker, are held directly by AIB and may be deemed to be beneficially owned by AIM, AIH and Mr. Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

**(c)**
The information set forth in Item 3 hereof is incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Item 3 hereof is incorporated herein by reference.

A Joint Filing Agreement, dated as of April 7, 2026, by and among the Reporting Persons has been executed by the Reporting Persons, a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** AI Biotechnology LLC

**Signature:** /s/ Alejandro Moreno

**Name/Title:** By: Access Industries Management, LLC, its Manager; its Executive Vice President/Alejandro Moreno

**Date:** 04/07/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Access Industries Holdings LLC

**Signature:** /s/ Alejandro Moreno

**Name/Title:** By: Access Industries Management, LLC, its Manager; its Executive Vice President/Alejandro Moreno

**Date:** 04/07/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Access Industries Management, LLC

**Signature:** /s/ Alejandro Moreno

**Name/Title:** By: Executive Vice President/Alejandro Moreno

**Date:** 04/07/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Len Blavatnik

**Signature:** *

**Name/Title:** Len Blavatnik

**Date:** 04/07/2026